Menu Search
Equities

Cerus Corp

CU2:FRA

Cerus Corp

Actions
Health CareMedical Equipment and Services
  • Price (EUR)1.57
  • Today's Change0.02 / 1.29%
  • Shares traded1.00k
  • 1 Year change+3.01%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 07:05 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Cerus Corp has grown net income from a loss of -42.78m to a smaller loss of -37.49m despite relatively flat revenues.
Gross margin60.52%
Net profit margin-10.00%
Operating margin-5.96%
Return on assets-10.01%
Return on equity-38.81%
Return on investment-15.26%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Cerus Corp fell by 24.00m. Cash Flow from Financing totalled 10.67m or 5.71% of revenues. In addition the company used 43.17m for operations while cash from investing totalled 8.62m.
Cash flow per share-0.096
Price/Cash flow per share--
Book value per share0.2882
Tangible book value per share0.2811
More ▼

Balance sheet in USDView more

Cerus Corp has a Debt to Total Capital ratio of 60.57%, a lower figure than the previous year's 124.13%.
Current ratio2.59
Quick ratio1.92
Total debt/total equity1.56
Total debt/total capital0.6057
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.